Skip to main content
Erschienen in: Drugs & Aging 7/2002

01.07.2002 | Review Article

Tolerability of Hypnosedatives in Older Patients

verfasst von: Dr Udo Wortelboer, Stefan Cohrs, Andrea Rodenbeck, Eckart Rüther

Erschienen in: Drugs & Aging | Ausgabe 7/2002

Einloggen, um Zugang zu erhalten

Abstract

Sleep disturbances are common and prevalence rates increase with age. Especially in the elderly, somatic diseases and medications with adverse effects relating to sleep are frequent reasons for disturbed and nonrefreshing sleep. It should be emphasised that these reasons must be excluded before symptomatic therapy is started. In some cases the use of hypnosedatives may be included as part of the treatment of a somatic disease and may cause sleep disturbances. Pharmacotherapy is one of the main approaches in the management of primary insomnia and should be part of a broader treatment strategy including nonpharmacological methods.
This article focuses on the tolerability of frequently prescribed hypnosedatives in the elderly with primary insomnia and addresses the primary care physician. In general, recommendations for the pharmacotherapy of insomnia in elderly patients include using a reduced dosage. For some substances (e.g. Zolpidem, zopiclone, zaleplon, temazepam and triazolam) the recommended dosage is half that recommended for younger patients. The properties of the selected hypnosedative should be taken into consideration and matched with the type of sleep disturbance experienced by the patient. Ultrashort-acting drugs may be useful when initiating sleep is the main problem, whereas shortand intermediate-acting substances are recommended for maintaining sleep. Possible interactions with pre-existing medication must also be taken into consideration.
Some agents such as antipsychotics, antidepressants, melatonin and herbal agents may be used in specific indications. However, only a few of these substances have proven tolerability in the elderly and further investigations are recommended.
Literatur
1.
Zurück zum Zitat Quera-Salva MA, Orluc A, Goldenberg F, et al. Insomnia and use of hypnotics: study of a French population. Sleep 1991; 14(5): 386–91PubMed Quera-Salva MA, Orluc A, Goldenberg F, et al. Insomnia and use of hypnotics: study of a French population. Sleep 1991; 14(5): 386–91PubMed
2.
Zurück zum Zitat Walsh J. Socio-economic costs of insomnia. Consensus Conference on Insomnia. Versaille: World Health Organization, 1996 Walsh J. Socio-economic costs of insomnia. Consensus Conference on Insomnia. Versaille: World Health Organization, 1996
3.
Zurück zum Zitat Meilinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry 1985; 42(3): 225–32CrossRef Meilinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry 1985; 42(3): 225–32CrossRef
4.
Zurück zum Zitat Hajak G. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci 2001; 251(2): 49–56PubMedCrossRef Hajak G. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci 2001; 251(2): 49–56PubMedCrossRef
5.
Zurück zum Zitat Chevalier H, Los F, Boichut D, et al. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol 1999; 13(4): S21–4PubMed Chevalier H, Los F, Boichut D, et al. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol 1999; 13(4): S21–4PubMed
7.
Zurück zum Zitat Woodward M. Insomnia in the elderly. Aust Fam Physician 1999; 7: 653–8 Woodward M. Insomnia in the elderly. Aust Fam Physician 1999; 7: 653–8
8.
Zurück zum Zitat Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000; 23Suppl. 1: S23–30PubMed Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000; 23Suppl. 1: S23–30PubMed
9.
Zurück zum Zitat Simen S, Rodenback A, Schlaf G, et al. Sleep complaints and hypnotic use by the elderly: results of a representative survey in West Germany [in German]. Wien Med Wochenschr 1996; 146(13–14): 306–9PubMed Simen S, Rodenback A, Schlaf G, et al. Sleep complaints and hypnotic use by the elderly: results of a representative survey in West Germany [in German]. Wien Med Wochenschr 1996; 146(13–14): 306–9PubMed
10.
Zurück zum Zitat Seppala M, Hyyppa MT, Impivaara O, et al. Subjective quality of sleep and use of hypnotics in an elderly urban population. Aging (Milano) 1997; 9(5): 327–34 Seppala M, Hyyppa MT, Impivaara O, et al. Subjective quality of sleep and use of hypnotics in an elderly urban population. Aging (Milano) 1997; 9(5): 327–34
11.
Zurück zum Zitat Wilkinson G. The effect of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psychiatr Scand 1978; 274: 56–74CrossRef Wilkinson G. The effect of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psychiatr Scand 1978; 274: 56–74CrossRef
12.
Zurück zum Zitat Grad RM. Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. J Fam Pract 1995; 41(5): 473–81PubMed Grad RM. Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. J Fam Pract 1995; 41(5): 473–81PubMed
13.
Zurück zum Zitat Vogel GW, Morris D. The effects of estazolam on sleep, performance, and memory: a long-term sleep laboratory study of elderly insomniacs. J Clin Pharmacol 1992; 32(7): 647–51PubMed Vogel GW, Morris D. The effects of estazolam on sleep, performance, and memory: a long-term sleep laboratory study of elderly insomniacs. J Clin Pharmacol 1992; 32(7): 647–51PubMed
14.
Zurück zum Zitat Hauri P. Sleep hygiene, relaxation therapy and cognitive interventions. In: Hauri P, editor. Case studies in insomnia. New York (NY): Plenum, 1991: 65–84 Hauri P. Sleep hygiene, relaxation therapy and cognitive interventions. In: Hauri P, editor. Case studies in insomnia. New York (NY): Plenum, 1991: 65–84
15.
Zurück zum Zitat Hajak G, Rüther E. Insomnie. Heidelberg: Springer, 1995 Hajak G, Rüther E. Insomnie. Heidelberg: Springer, 1995
16.
Zurück zum Zitat Clarenbach P, Steinberg R, Weess HG, et al. Empfehlungen zu Diagnostik und Therapie der Insomnie (DGSM). Nervenarzt 1995; 66(10): 723–9PubMed Clarenbach P, Steinberg R, Weess HG, et al. Empfehlungen zu Diagnostik und Therapie der Insomnie (DGSM). Nervenarzt 1995; 66(10): 723–9PubMed
17.
Zurück zum Zitat Walsh J, Benca R, Bonnet M, et al. Insomnia: assessment and management in primary care. Bethesda (MD): National Institute of Health, 1998 Walsh J, Benca R, Bonnet M, et al. Insomnia: assessment and management in primary care. Bethesda (MD): National Institute of Health, 1998
18.
Zurück zum Zitat The World Psychiatric Association. T.W.P.A Task Force on sedative hypnotics. Eur Psychiatr 1993; 8: 45–9 The World Psychiatric Association. T.W.P.A Task Force on sedative hypnotics. Eur Psychiatr 1993; 8: 45–9
19.
Zurück zum Zitat Hajak G, Cluydts R, Estivill E, et al. Efficacy of discontinuous Zolpidem in primary insomnia [abstract]. World J Biol Psychiatr 2001; 2Suppl. 1: P033–01 Hajak G, Cluydts R, Estivill E, et al. Efficacy of discontinuous Zolpidem in primary insomnia [abstract]. World J Biol Psychiatr 2001; 2Suppl. 1: P033–01
20.
Zurück zum Zitat Cluydts R, Peeters K, de Bouyalsky I, et al. Comparison of continuous versus intermittent administration of Zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998; 26(1): 13–24PubMed Cluydts R, Peeters K, de Bouyalsky I, et al. Comparison of continuous versus intermittent administration of Zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998; 26(1): 13–24PubMed
21.
Zurück zum Zitat Walsh JK, Roth T, Randazzo A, et al. Eight weeks of nonnightly use of Zolpidem for primary insomnia. Sleep 2000; 23(8): 1087–96PubMed Walsh JK, Roth T, Randazzo A, et al. Eight weeks of nonnightly use of Zolpidem for primary insomnia. Sleep 2000; 23(8): 1087–96PubMed
22.
Zurück zum Zitat Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994; 4(1): 9–20PubMedCrossRef Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994; 4(1): 9–20PubMedCrossRef
23.
Zurück zum Zitat Hajak G. Insomnia in primary care. Sleep 2000; 23Suppl. 3: S54–63PubMed Hajak G. Insomnia in primary care. Sleep 2000; 23Suppl. 3: S54–63PubMed
24.
Zurück zum Zitat Hakamies-Blomqvist L, Johansson K, Lundberg C. Medical screening of older drivers as a traffic safety measure — a comparative Finnish-Swedish evaluation study. J Am Geriatr Soc 1996; 44(6): 650–3PubMed Hakamies-Blomqvist L, Johansson K, Lundberg C. Medical screening of older drivers as a traffic safety measure — a comparative Finnish-Swedish evaluation study. J Am Geriatr Soc 1996; 44(6): 650–3PubMed
25.
Zurück zum Zitat Nakra BR, Gfeller JD, Hassan R. A double-blind comparison of the effects of temazepam and triazolam on residual, daytime performance in elderly insomniacs. It Psychogeriatr 1992; 4(1): 45–53CrossRef Nakra BR, Gfeller JD, Hassan R. A double-blind comparison of the effects of temazepam and triazolam on residual, daytime performance in elderly insomniacs. It Psychogeriatr 1992; 4(1): 45–53CrossRef
26.
Zurück zum Zitat Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23): 3303–7PubMedCrossRef Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23): 3303–7PubMedCrossRef
27.
Zurück zum Zitat Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47(1): 30–9PubMed Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47(1): 30–9PubMed
28.
Zurück zum Zitat Blain H, Blain A, Trechot P, et al. The role of drugs in falls in the elderly: epidemiologic aspects [in french]. Presse Med 2000; 29(12): 673–80PubMed Blain H, Blain A, Trechot P, et al. The role of drugs in falls in the elderly: epidemiologic aspects [in french]. Presse Med 2000; 29(12): 673–80PubMed
29.
Zurück zum Zitat Forsen L, Meyer HE, Sogaard AJ, et al. Mental distress and risk of hip fracture: do broken hearts lead to broken bones? J Epidemiol Community Health 1999; 53(6): 343–7PubMedCrossRef Forsen L, Meyer HE, Sogaard AJ, et al. Mental distress and risk of hip fracture: do broken hearts lead to broken bones? J Epidemiol Community Health 1999; 53(6): 343–7PubMedCrossRef
30.
Zurück zum Zitat Moore N, Pierfitte C, Pehourcq F, et al. Comparison of patient questionnaires, medical records and plasma assays in assessing exposure to benzodiazepines in elderly subjects. Clin Pharmacol Ther 2001; 69(6): 445–50PubMedCrossRef Moore N, Pierfitte C, Pehourcq F, et al. Comparison of patient questionnaires, medical records and plasma assays in assessing exposure to benzodiazepines in elderly subjects. Clin Pharmacol Ther 2001; 69(6): 445–50PubMedCrossRef
31.
Zurück zum Zitat Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of Zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993; 15(1): 127–36PubMed Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of Zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993; 15(1): 127–36PubMed
32.
Zurück zum Zitat Vgontzas AN, Kales A, Bixler EO, et al. Temazepam 7.5 mg: effects on sleep in elderly insomniacs. Eur J Clin Pharmacol 1994; 46(3): 209–13PubMedCrossRef Vgontzas AN, Kales A, Bixler EO, et al. Temazepam 7.5 mg: effects on sleep in elderly insomniacs. Eur J Clin Pharmacol 1994; 46(3): 209–13PubMedCrossRef
33.
Zurück zum Zitat Overstall PW, Oldman PN. A comparative study of lormetazepam and chlormethiazole in elderly in-patients. Age Ageing 1987; 16(1): 45–51PubMedCrossRef Overstall PW, Oldman PN. A comparative study of lormetazepam and chlormethiazole in elderly in-patients. Age Ageing 1987; 16(1): 45–51PubMedCrossRef
34.
Zurück zum Zitat Wheatley D. Prescribing short-acting hypnosedatives. Current recommendations from a safety perspective. Drug Saf 1992; 7(2): 106–15PubMedCrossRef Wheatley D. Prescribing short-acting hypnosedatives. Current recommendations from a safety perspective. Drug Saf 1992; 7(2): 106–15PubMedCrossRef
35.
Zurück zum Zitat Camacho ME, Morin CM. The effect of temazepam on respiration in elderly insomniacs with mild sleep apnea. Sleep 1995; 18(8): 644–5PubMed Camacho ME, Morin CM. The effect of temazepam on respiration in elderly insomniacs with mild sleep apnea. Sleep 1995; 18(8): 644–5PubMed
36.
Zurück zum Zitat Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Vol. 2. Berlin: Springer, 2000 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Vol. 2. Berlin: Springer, 2000
37.
Zurück zum Zitat Darcourt G, Pringuey D, Salliere D, et al. The safety and tolerability of Zolpidem: an update. J Psychopharmacol 1999; 13(1): 81–93PubMedCrossRef Darcourt G, Pringuey D, Salliere D, et al. The safety and tolerability of Zolpidem: an update. J Psychopharmacol 1999; 13(1): 81–93PubMedCrossRef
38.
Zurück zum Zitat Hajak G. A comparative assessment of the risks and benefits of zopiclone: a review of 15 years’ clinical experience. Drug Saf 1999; 21(6): 457–69PubMedCrossRef Hajak G. A comparative assessment of the risks and benefits of zopiclone: a review of 15 years’ clinical experience. Drug Saf 1999; 21(6): 457–69PubMedCrossRef
39.
Zurück zum Zitat Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59(4): 865–89PubMedCrossRef Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59(4): 865–89PubMedCrossRef
40.
Zurück zum Zitat Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55(2): 277–302PubMedCrossRef Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55(2): 277–302PubMedCrossRef
41.
Zurück zum Zitat Shaw S, Curson H, Coquelin J. A double-blind, comparative study of Zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992; 20: 150–61PubMed Shaw S, Curson H, Coquelin J. A double-blind, comparative study of Zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992; 20: 150–61PubMed
42.
Zurück zum Zitat Fachinformation Sonata 5mg/-10mg® [prescribing information]. Berkshire: Wyeth Europe Ltd, 2001. Fachinformation Sonata 5mg/-10mg® [prescribing information]. Berkshire: Wyeth Europe Ltd, 2001.
43.
Zurück zum Zitat Eckert A, Reiff J, Muller ME. Medical interactions with antidepressives: benefits of the specific serotonin reuptake inhibitor Citalopram [in German]. Med Monatsschr Pharm 1998; 21(5): 138–50PubMed Eckert A, Reiff J, Muller ME. Medical interactions with antidepressives: benefits of the specific serotonin reuptake inhibitor Citalopram [in German]. Med Monatsschr Pharm 1998; 21(5): 138–50PubMed
44.
Zurück zum Zitat George CF. Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep 2000; 23Suppl. 1: S31–5PubMed George CF. Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep 2000; 23Suppl. 1: S31–5PubMed
45.
46.
Zurück zum Zitat Hedner J, Yaeche R, Emilien G, et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatr 2000; 15(8): 704–12CrossRef Hedner J, Yaeche R, Emilien G, et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatr 2000; 15(8): 704–12CrossRef
47.
Zurück zum Zitat Pichard L, Gillet G, Bonfils C, et al. Oxidative metabolism of Zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23(11): 1253–62PubMed Pichard L, Gillet G, Bonfils C, et al. Oxidative metabolism of Zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23(11): 1253–62PubMed
48.
Zurück zum Zitat Copinschi G, Akseki R, Moreno-Reyes R, et al. Effects of bedtime administration of Zolpidem on circadian and sleeprelated hormonal profiles in normal women. Sleep 1995; 18(6): 417–24PubMed Copinschi G, Akseki R, Moreno-Reyes R, et al. Effects of bedtime administration of Zolpidem on circadian and sleeprelated hormonal profiles in normal women. Sleep 1995; 18(6): 417–24PubMed
49.
Zurück zum Zitat Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs: a review. Psychopharmacology (Berl) 1996; 126(1): 1–16CrossRef Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs: a review. Psychopharmacology (Berl) 1996; 126(1): 1–16CrossRef
50.
Zurück zum Zitat Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of Zolpidem in normal geriatric subjects. J Clin Psychiatry 1991; 52(2): 77–83PubMed Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of Zolpidem in normal geriatric subjects. J Clin Psychiatry 1991; 52(2): 77–83PubMed
51.
Zurück zum Zitat Walsh J, Roehrs T, Declerck A. Polysomnographic studies of the effects of Zolpidem in patients with insomnia. In: Freeman H, Puech A, Roth TE, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996: 129–39 Walsh J, Roehrs T, Declerck A. Polysomnographic studies of the effects of Zolpidem in patients with insomnia. In: Freeman H, Puech A, Roth TE, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996: 129–39
52.
Zurück zum Zitat Monti J, Monti D. Pharmacological treatment of chronic insomnia. CNS Drugs 1995; 4: 182–94CrossRef Monti J, Monti D. Pharmacological treatment of chronic insomnia. CNS Drugs 1995; 4: 182–94CrossRef
53.
Zurück zum Zitat Guerault E, Chaumet-Riffaud A, Morselli P. Neurological adverse event profile in the elderly with Zolpidem 5 mg and 10 mg: a retrospective evaluation of European phase II and III studies [abstract]. J Sleep Res 1992; 1Suppl. 1: 89 Guerault E, Chaumet-Riffaud A, Morselli P. Neurological adverse event profile in the elderly with Zolpidem 5 mg and 10 mg: a retrospective evaluation of European phase II and III studies [abstract]. J Sleep Res 1992; 1Suppl. 1: 89
54.
Zurück zum Zitat Chaumet-Riffaud A, Desforges C, Lavoisy J. Review of the post-marketing surveillance experience collected with Zolpidem during the first three years after launch in Europe [abstract]. J Sleep Res 1992; 1Suppl. 1: 40 Chaumet-Riffaud A, Desforges C, Lavoisy J. Review of the post-marketing surveillance experience collected with Zolpidem during the first three years after launch in Europe [abstract]. J Sleep Res 1992; 1Suppl. 1: 40
55.
Zurück zum Zitat Unden M, Roth-Schechter B. Next day effects after nighttime treatment with Zolpidem: a review. Eur Psychiatry 1996; 11Suppl. 1: 21S–30SCrossRef Unden M, Roth-Schechter B. Next day effects after nighttime treatment with Zolpidem: a review. Eur Psychiatry 1996; 11Suppl. 1: 21S–30SCrossRef
56.
Zurück zum Zitat Shelton PS, Hocking LB. Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother 1997; 31(3): 319–22PubMed Shelton PS, Hocking LB. Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother 1997; 31(3): 319–22PubMed
57.
Zurück zum Zitat Klimm HD, Dreyfus JF, Delmotte M. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep 1987; 10 Suppl. 1: 73–8 Klimm HD, Dreyfus JF, Delmotte M. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep 1987; 10 Suppl. 1: 73–8
58.
Zurück zum Zitat Lofaso F, Goldenberg F, Thebault C, et al. Effect of zopiclone on sleep, night-time ventilation, and daytime vigilance in upper airway resistance syndrome. Eur Respir J 1997; 10(11): 2573–7PubMedCrossRef Lofaso F, Goldenberg F, Thebault C, et al. Effect of zopiclone on sleep, night-time ventilation, and daytime vigilance in upper airway resistance syndrome. Eur Respir J 1997; 10(11): 2573–7PubMedCrossRef
59.
Zurück zum Zitat Elie R, Frenay M, Le Morvan P, et al. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 1990; 5Suppl. 2: 39–46PubMed Elie R, Frenay M, Le Morvan P, et al. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 1990; 5Suppl. 2: 39–46PubMed
60.
Zurück zum Zitat Dehlin O, Rubin B, Rundgren A. Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects. Curr Med Res Opin 1995; 13(6): 317–24PubMedCrossRef Dehlin O, Rubin B, Rundgren A. Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects. Curr Med Res Opin 1995; 13(6): 317–24PubMedCrossRef
61.
Zurück zum Zitat Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999; 22(3): 371–5PubMed Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999; 22(3): 371–5PubMed
62.
Zurück zum Zitat Corey-Bloom J, Galasko D. Adjunctive therapy in patients with Alzheimer’s disease: a practical approach. Drugs Aging 1995; 7(2): 79–87PubMedCrossRef Corey-Bloom J, Galasko D. Adjunctive therapy in patients with Alzheimer’s disease: a practical approach. Drugs Aging 1995; 7(2): 79–87PubMedCrossRef
63.
Zurück zum Zitat Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, Polysomnographie study. J Clin Psychiatry 2001; 62(6): 453–63PubMedCrossRef Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, Polysomnographie study. J Clin Psychiatry 2001; 62(6): 453–63PubMedCrossRef
64.
Zurück zum Zitat Vorderholzer U, Berger M, Hohagen F, et al. Trimipramine for primary insomnia: a double-blind, randomized controlled study [abstract]. World J Biol Psychiatry 2001; 2Suppl. 1: 0012–02 Vorderholzer U, Berger M, Hohagen F, et al. Trimipramine for primary insomnia: a double-blind, randomized controlled study [abstract]. World J Biol Psychiatry 2001; 2Suppl. 1: 0012–02
65.
Zurück zum Zitat Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10Suppl. 4: 37–45PubMedCrossRef Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10Suppl. 4: 37–45PubMedCrossRef
66.
Zurück zum Zitat Zisapel N. The use of melatonin for the treatment of insomnia. Biol Signals Recept 1999; 8(1–2): 84–9PubMedCrossRef Zisapel N. The use of melatonin for the treatment of insomnia. Biol Signals Recept 1999; 8(1–2): 84–9PubMedCrossRef
67.
Zurück zum Zitat Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346(8974): 541–4PubMedCrossRef Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346(8974): 541–4PubMedCrossRef
68.
Zurück zum Zitat Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18(7): 598–603PubMed Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18(7): 598–603PubMed
69.
Zurück zum Zitat Iguchi H, Kato K, Ibasayhi H. Age-dependent reduction in serum melatonin concentration in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27–9CrossRef Iguchi H, Kato K, Ibasayhi H. Age-dependent reduction in serum melatonin concentration in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27–9CrossRef
70.
Zurück zum Zitat Skene DJ, Vivien-Roels B, Sparks DL, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease. Brain Res 1990; 528(1): 170–4PubMedCrossRef Skene DJ, Vivien-Roels B, Sparks DL, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease. Brain Res 1990; 528(1): 170–4PubMedCrossRef
71.
Zurück zum Zitat Brusco LI, Fainstein I, Marquez M, et al. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept 1999; 8(1–2): 126–31PubMedCrossRef Brusco LI, Fainstein I, Marquez M, et al. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept 1999; 8(1–2): 126–31PubMedCrossRef
72.
Zurück zum Zitat Kendler BS. Melatonin: media hype or therapeutic breakthrough? Nurse Pract 1997; 22(2): 66–7, 71-2, 77PubMedCrossRef Kendler BS. Melatonin: media hype or therapeutic breakthrough? Nurse Pract 1997; 22(2): 66–7, 71-2, 77PubMedCrossRef
73.
Zurück zum Zitat Olde Rikkert MG, Rigaud AS. Melatonin in elderly patients with insomnia: a systematic review. Z Gerontol Geriatr 2001; 34(6): 491–7PubMedCrossRef Olde Rikkert MG, Rigaud AS. Melatonin in elderly patients with insomnia: a systematic review. Z Gerontol Geriatr 2001; 34(6): 491–7PubMedCrossRef
74.
Zurück zum Zitat Beaubrun G, Gray GE. A review of herbal medicines for psychiatric disorders. Psychiatr Serv 2000; 51(9): 1130–4PubMedCrossRef Beaubrun G, Gray GE. A review of herbal medicines for psychiatric disorders. Psychiatr Serv 2000; 51(9): 1130–4PubMedCrossRef
75.
Zurück zum Zitat Ernst E. Herbal medications for common ailments in the elderly. Drugs Aging 1999; 15(6): 423–8PubMedCrossRef Ernst E. Herbal medications for common ailments in the elderly. Drugs Aging 1999; 15(6): 423–8PubMedCrossRef
76.
Zurück zum Zitat Nachtmann A, Hajak G. Phytopharmaceutic drugs in treatment of sleep disorders [in German]. Internist (Berl) 1996; 37(7): 743–9 Nachtmann A, Hajak G. Phytopharmaceutic drugs in treatment of sleep disorders [in German]. Internist (Berl) 1996; 37(7): 743–9
77.
Zurück zum Zitat Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998; 32(6): 680–91PubMedCrossRef Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998; 32(6): 680–91PubMedCrossRef
78.
Zurück zum Zitat Gold JL, Laxer DA, Dergal JM, et al. Herbal-drug therapy interactions: a focus on dementia. Curr Opin Clin Nutr Metab Care 2001; 4(1): 29–34PubMedCrossRef Gold JL, Laxer DA, Dergal JM, et al. Herbal-drug therapy interactions: a focus on dementia. Curr Opin Clin Nutr Metab Care 2001; 4(1): 29–34PubMedCrossRef
Metadaten
Titel
Tolerability of Hypnosedatives in Older Patients
verfasst von
Dr Udo Wortelboer
Stefan Cohrs
Andrea Rodenbeck
Eckart Rüther
Publikationsdatum
01.07.2002
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 7/2002
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200219070-00006

Weitere Artikel der Ausgabe 7/2002

Drugs & Aging 7/2002 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.